中国生物科技服务(08037) - 2023 - 年度业绩

Supplementary Announcement This supplementary announcement updates the annual report for the year ended December 31, 2022, regarding net proceeds usage Announcement Overview This supplementary announcement from China Biotech Services Holdings Limited updates the 2022 annual report, primarily on net proceeds usage - The announcement is a supplementary announcement, providing further details for the annual report for the year ended December 31, 2022[2][7] - The issuing company is China Biotech Services Holdings Limited (Stock Code: 8037)[7] - This announcement supplements the company's annual report published on March 29, 2023, for the year ended December 31, 2022[7] Update on Use of Net Proceeds The company updated the proposed use of net proceeds for 2022, detailing unutilized balances and timelines for BNCT project, R&D, and working capital, with no material changes confirmed Investment in Boron Neutron Capture Therapy Project This section details the allocation and expected utilization timeline for net proceeds designated for the BNCT project Use of Net Proceeds for Boron Neutron Capture Therapy Project (As of December 31, 2022) | Proposed Use | Net Proceeds (HKD '000) | Net Proceeds (USD) | Used as of Dec 31, 2022 (HKD '000) | Balance as of Dec 31, 2022 (HKD '000) | Proposed Use and Expected Timeline | | :--- | :--- | :--- | :--- | :--- | :--- | | Investment in Boron Neutron Capture Therapy Project | 23,340 | 3,000,000 | None | 23,340 | The remaining unutilized amount of HKD 23,340,000 will be used for investment in the Boron Neutron Capture Therapy project, expected to be fully utilized by September 30, 2023 at the latest | R&D Costs and General Working Capital This section outlines the allocation and expected utilization timeline for net proceeds designated for R&D and general working capital Use of Net Proceeds for R&D Costs and General Working Capital (As of December 31, 2022) | Proposed Use | Net Proceeds (HKD '000) | Net Proceeds (USD) | Used as of Dec 31, 2022 (HKD '000) | Balance as of Dec 31, 2022 (HKD '000) | Proposed Use and Expected Timeline | | :--- | :--- | :--- | :--- | :--- | :--- | | R&D Costs and General Working Capital | 15,124 | 1,944,000 | None | 15,124 | The remaining unutilized amount of HKD 15,124,000 will be used for R&D costs and general working capital, expected to be fully utilized by September 30, 2023 at the latest | - The primary update concerns the proposed use of net proceeds as presented in the table on page 18 of the annual report[8] - The Board confirmed that the net proceeds have been or are intended to be used in accordance with previously disclosed intentions, and directors are unaware of any material changes to the proposed use[10] Board Members The Board of Directors comprises seven members: three executive, one non-executive, and three independent non-executive directors - The Board of Directors consists of seven members[5] - Executive Directors include Mr Liu Xiaolin (Chairman), Mr He Xun, and Mr Huang Song[5] - Non-Executive Director includes Ms Xu Haiyin[5] - Independent Non-Executive Directors include Mr Yan Guoxiang, Dr He Junjie, and Mr Qian Hongji[5] Other Important Information and Disclaimer All other annual report information remains unchanged; the Board assumes full responsibility for this announcement's accuracy and completeness - All other information contained in the annual report remains unchanged, except as disclosed in this announcement[11] - This announcement is published in compliance with the GEM Listing Rules of The Stock Exchange of Hong Kong Limited, aiming to provide information about the company[12] - The Directors collectively and individually accept full responsibility for the information in this announcement, confirming its accuracy, completeness, and absence of misleading or fraudulent content or omissions[12] - This announcement will be published on the website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the company's website (www.cbshhk.com) for at least seven consecutive days from the date of publication[12] - Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited assume no responsibility for the contents of this announcement and make no representation as to its accuracy or completeness[1]